logo
West Leyden High School senior awaiting heart transplant graduates at Lurie Children's Hospital

West Leyden High School senior awaiting heart transplant graduates at Lurie Children's Hospital

Chicago Tribune21-05-2025
It had all the makings of a typical graduation party. Blue and yellow streamers lined the room. Signs were posted on the walls that said 'Congrats Grad 2025,' 'You did it' and 'Made the grade.' In the back, there was a table full of Chips Ahoy and Oreos and even a cake that read 'Congratulations Taevion' in blue frosting.
Except, the party was held on the 22nd floor of Lurie Children's Hospital in honor of one of the hospital's patients: 18-year-old Taevion Norris. He had been attending West Leyden High School in Northlake when his senior year was suddenly interrupted in March due to heart failure, forcing him to spend the tail end of his final year of high school in the hospital.
But Norris refused to let his condition stop him from graduating on time — and succeeded. On Wednesday, Norris — wearing a blue cap and gown — was handed his diploma. Graduation music played in the background as he traversed from one end of the hospital hallway into the room of the ceremony.
'This is a very good day. Despite what he's going through, he was still able to graduate with his class,' Tainica Norris, Taevion's mother, said. 'It's good that he has a big crowd to see him achieve and accomplish one of his dreams and his goals, and just to be loved by everybody, because nobody knows what it's like to face what he has.'
In 2019, her eldest son was diagnosed with Duchenne muscular dystrophy, a neuromuscular condition where the body is unable to make dystrophin — a protein that helps keep muscles together. Without dystrophin, muscles in various parts of the body — such as the legs, arms and heart — get replaced with fibrous tissue. That can lead to bigger health issues, such as heart failure and losing the ability to walk.
Norris was in elementary school when one day, his mother received a phone call from the gym teacher.
'I was at work and he told me that I needed to get Taevion tested,' she recalled. 'And I'm like, 'What's going on?' He was like, 'I noticed that Taevion is not moving like he used to move, like his pace has slowed down.''
Norris was eventually referred to Dr. Katheryn Gambetta, a pediatric cardiologist at Lurie Children's Hospital. Gambetta said that Norris 'was around 12 or 13' when he was diagnosed and said that he was 'coming in at least every six months.'
'But he actually had heart dysfunction, probably when he was around 15, and then over time, that just got worse and worse,' Gambetta said. 'This is what we see — that heart dysfunction gets worse over time in boys and that the leading cause of death in boys who have Duchenne muscular dystrophy is due to heart failure.'
In the past year, Norris — who uses a wheelchair — had been admitted to the hospital multiple times, but his admittance about two months ago was unlike any of the others.
'Two months ago, he got really, really sick. He wasn't sleeping, he wasn't eating, he was just throwing up,' his mother recalled.
One morning, around 3 a.m., Norris called his mom and she found vomit everywhere in the bathroom, prompting her to call the ambulance. On March 11, Norris was admitted as an inpatient to the hospital, which he was not happy about.
'And he said, 'Mama, see I told you I didn't want to come here because I knew they were gonna keep me here. I want to go back to school,'' his mother said. 'I said, 'Taevion, it's either that or you're not gonna be here.''
The journey to get her son to graduation has not been an easy one.
'I stopped working because it started getting tough,' Norris' mother said. 'Kept going to the doctor, he kept getting more sicker, missing a lot of school, calling the school, let them know what's going on. It's just been hard.'
Norris' mother initially did not think that her son would be able to graduate on time while in the hospital. 'I thought it was gonna be a struggle, but he proved me wrong,' she said.
While it was not the first time Lurie Children's Hospital had a graduation for a student, the level of care from West Leyden High School that was put into helping Norris graduate was noted by the staff at Lurie Children's Hospital, making this one feel extra special.
Hana Herrick, a school services coordinator for Lurie Children's Hospital, said that she started working with Norris when he was admitted about two and a half months ago.
'Taevion can be very stoic at times, and he is very shy,' Herrick said. Finishing up school for Norris looked like a hybrid model, where he would have online classes with an instructor from his high school and Herrick by his side for additional in-person support.
Providing those online classes, Herrick said, was 'out of the norm.'
'Most schools don't do that for their students, so that was awesome,' Herrick said.
One of Herrick's favorite moments with him was when she told him that he had one task left, which was around the same time the two started working together: tackle George Orwell's novel 'Animal Farm.'
'The smile that came across his face was just so memorable,' Herrick said. 'And he was like, 'Whoa, really.' Like he couldn't believe it.'
Herrick said she was worried initially about how Norris was going to perceive the book, but those worries soon faded into the background. Not only did Norris finish reading the whole book, but he watched both movie adaptations and came up with rigorous reading comprehension questions.
As for next steps, Norris is on a waiting list for a heart transplant. According to Gambetta, he's been on the list for a heart transplant since May 1. Gambetta said she is hopeful that Norris will get his heart transplant soon, noting that he's been given an Impella ventricular assist device to allow him time to get a transplant. His family is also fundraising for a minivan through the Jett Foundation in order to make traveling together as a family easier.
Beyond the heart transplant, what career path Norris will pick is still up in the air, but his mother did note that he had previously considered being an NBA commentator.
'He wanted to be that. So I said, 'OK, well, you're gonna have to work for it. You're gonna have to learn how to do what they do and say what they say, and learn how to dress — well, he knows how to dress himself,' his mother said. 'So hopefully that might still be his pathway.'
But regardless of his journey, one thing was made clear as he was handed his diploma by Nick Polyak, superintendent of Leyden High School District 212.
'No matter where you go and what you do, you will always be a Leyden Eagle,' Polyak said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sarepta says eight-year-old death deemed unrelated to Elevidys
Sarepta says eight-year-old death deemed unrelated to Elevidys

Business Insider

time6 hours ago

  • Business Insider

Sarepta says eight-year-old death deemed unrelated to Elevidys

Sarepta (SRPT) said in a statement Friday night: 'Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy patient who had received Elevidys gene therapy. The death of this patient was deemed unrelated to treatment with Elevidys…Sarepta reported this event to FDA on June 18, 2025, via the FDA's postmarketing electronic database, FAERS. At Sarepta, patient safety and well-being are always our top priority. We are committed to upholding the highest safety standards for all of our therapies, and do so in accordance with applicable law and commitment to full regulatory transparency. Elevidys is the only approved gene therapy for families and children devastated by Duchenne, a rare, progressive and ultimately fatal disease. We remain committed to working closely with the FDA to ensure that all decisions are grounded in science and the best interests of patients, considering the compelling need of these families to access disease-modifying therapy.' Elevate Your Investing Strategy:

FDA investigating death of child who received Sarepta's Elevidys
FDA investigating death of child who received Sarepta's Elevidys

Business Insider

time2 days ago

  • Business Insider

FDA investigating death of child who received Sarepta's Elevidys

The U.S. FDA is investigating the death of an 8-year-old boy who received Elevidys, a Sarepta (SRPT) Therapeutics gene therapy for Duchenne muscular dystrophy. The death occurred on June 7, 2025. The FDA has requested and received voluntary suspension of product distribution as it investigates the safety concerns. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS
Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS

Yahoo

time2 days ago

  • Yahoo

Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS

CAMBRIDGE, Mass., July 25, 2025--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration (FDA) issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy (Duchenne) patient who had received ELEVIDYS (delandistrogene moxeparvovec) gene therapy. The death of this patient was deemed unrelated to treatment with ELEVIDYS. As reported yesterday by Naomi Kresge at Bloomberg News: Roche Holding AG says the recent death of a patient in Brazil who had been treated with gene therapy Elevidys for Duchenne muscular dystrophy is unrelated to the treatment. * The boy wasn't a clinical trial participant; reporting physician assessed his death as being unrelated to the gene therapy, Roche says in statement* Death was reported to health authorities* Roche, which markets Sarepta's Duchenne treatment Elevidys outside the US, declines to comment on the boy's age or details of the case Sarepta reported this event to FDA on June 18, 2025, via the FDA's postmarketing electronic database, FAERS. At Sarepta, patient safety and well-being are always our top priority. We are committed to upholding the highest safety standards for all of our therapies, and do so in accordance with applicable law and commitment to full regulatory transparency. ELEVIDYS is the only approved gene therapy for families and children devastated by Duchenne, a rare, progressive and ultimately fatal disease. We remain committed to working closely with the FDA to ensure that all decisions are grounded in science and the best interests of patients, considering the compelling need of these families to access disease-modifying therapy. About ELEVIDYS (delandistrogene moxeparvovec-rokl)ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle. ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in the DMD gene For patients who are non-ambulatory and have a confirmed mutation in the DMD gene. The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). IMPORTANT SAFETY INFORMATION CONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. WARNINGS AND PRECAUTIONS:Infusion-related Reactions: Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or up to several hours following ELEVIDYS administration. Closely monitor patients during administration and for at least 3 hours after the end of infusion. If symptoms of infusion-related reactions occur, slow, or stop the infusion and give appropriate treatment. Once symptoms resolve, the infusion may be restarted at a lower rate. ELEVIDYS should be administered in a setting where treatment for infusion-related reactions is immediately available. Discontinue infusion for anaphylaxis. Acute Serious Liver Injury: Acute serious liver injury has been observed with ELEVIDYS, and administration may result in elevations of liver enzymes (such as GGT, GLDH, ALT, AST) or total bilirubin, typically seen within 8 weeks. Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (e.g., acute hepatic viral infection) may be at higher risk of acute serious liver injury. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled. Prior to ELEVIDYS administration, perform liver enzyme test and monitor liver function (clinical exam, GGT, and total bilirubin) weekly for the first 3 months following ELEVIDYS infusion. Continue monitoring if clinically indicated, until results are unremarkable (normal clinical exam, GGT, and total bilirubin levels return to near baseline levels). Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated. If acute serious liver injury is suspected, consultation with a specialist is recommended. Immune-mediated Myositis: In clinical trials, immune-mediated myositis has been observed approximately 1 month following ELEVIDYS infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the DMD gene. Symptoms of severe muscle weakness, including dysphagia, dyspnea, and hypophonia, were observed. Limited data are available for ELEVIDYS treatment in patients with mutations in the DMD gene in exons 1 to 17 and/or exons 59 to 71. Patients with deletions in these regions may be at risk for a severe immune-mediated myositis reaction. Advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea, or hypophonia, as these may be symptoms of myositis. Consider additional immunomodulatory treatment (immunosuppressants [e.g., calcineurin-inhibitor] in addition to corticosteroids) based on patient's clinical presentation and medical history if these symptoms occur. Myocarditis: Acute serious myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion in clinical trials. If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes. Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated. More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath. Advise patients to contact a physician immediately if they experience cardiac symptoms. Preexisting Immunity against AAVrh74: In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all patients developed anti-AAVrh74 antibodies. Perform baseline testing for presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration. ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers greater than or equal to 1:400. Adverse Reactions: The most common adverse reactions (incidence ≥5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, and thrombocytopenia. Report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782). For further information, please see the full Prescribing Information. About Sarepta TherapeuticsSarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Forward-Looking StatementsThis statement contains "forward-looking statements." Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "anticipate," "plan," "expect," "will," "may," "intend," "prepare," "look," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, research and development programs, clinical trials and ELEVIDYS. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing approval; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business; and those risks identified under the heading "Risk Factors" in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to review. Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained herein. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law. Internet Posting of InformationWe routinely post information that may be important to investors in the 'For Investors' section of our website at We encourage investors and potential investors to consult our website regularly for important information about us. Source: Sarepta Therapeutics, Inc. View source version on Contacts Investor Contact: Ian Estepan617-274-4052iestepan@ Media Contacts: Tracy Sorrentino617-301-8566tsorrentino@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store